tetano
Editor, Senior Moderator
J Med Virol
. 2023 Apr;95(4):e28742.
doi: 10.1002/jmv.28742. Clinical observation of neutralizing antibody DXP-604 for treatment critical COVID-19 patients infected with SARS-CoV-2 Delta variant
Lijuan Chen[SUP] 1 [/SUP], Zehua Shao[SUP] 2 [/SUP], Hongmei Liu[SUP] 3 [/SUP], Qian Shi[SUP] 4 [/SUP], Chuanjian Lv[SUP] 1 [/SUP], Yan Bai[SUP] 1 [/SUP], Ziai Wu[SUP] 4 [/SUP], Wei Wei[SUP] 1 [/SUP], Huanhuan Wei[SUP] 1 [/SUP], Haiyan Gao[SUP] 1 [/SUP], Meiyun Wang[SUP] 1 [/SUP]
Affiliations
From January to March 2022, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) infection was prevalent in Yuzhou and Zhengzhou. DXP-604 is a broad-spectrum antiviral monoclonal antibody, which has excellent viral neutralization ability in vitro and a long half-life in vivo, with good biosafety and tolerability. Preliminary results showed that DXP-604 can accelerate recovery from Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 Delta variant in hospitalized patients with mild to moderate clinical symptoms. However, the efficacy of DXP-604 has not been fully studied in high-risk severe patients. Here, we prospectively enrolled 27 high-risk patients, two groups were divided, in addition to receiving standard of care (SOC), 14 of them additionally received the neutralizing antibody DXP-604 therapy, and another 13 intensive care unit (ICU) patients simultaneously underwent SOC as a control group matched for age, gender, and clinical type. The results revealed lower C-reactive protein, interleukin-6, lactic dehydrogenase and neutrophil counts, and higher lymphocyte and monocyte counts from Day 3 post-DXP-604 treatment compared with SOC treatment. Besides, thoracic CT images showed improvements in lesion areas and degrees, along with changes in blood inflammatory factors. Moreover, DXP-604 reduced the invasive mechanical ventilation and mortality of high-risk SARS-CoV-2 infected patients. The ongoing clinical trials of DXP-604 neutralizing antibody will clarify its utility as a new attractive countermeasure for high-risk COVID-19.
Keywords: COVID-19; DXP-604; intensive care unit patients; neutralizing antibody.
. 2023 Apr;95(4):e28742.
doi: 10.1002/jmv.28742. Clinical observation of neutralizing antibody DXP-604 for treatment critical COVID-19 patients infected with SARS-CoV-2 Delta variant
Lijuan Chen[SUP] 1 [/SUP], Zehua Shao[SUP] 2 [/SUP], Hongmei Liu[SUP] 3 [/SUP], Qian Shi[SUP] 4 [/SUP], Chuanjian Lv[SUP] 1 [/SUP], Yan Bai[SUP] 1 [/SUP], Ziai Wu[SUP] 4 [/SUP], Wei Wei[SUP] 1 [/SUP], Huanhuan Wei[SUP] 1 [/SUP], Haiyan Gao[SUP] 1 [/SUP], Meiyun Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 37185844
- DOI: 10.1002/jmv.28742
From January to March 2022, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta (B.1.617.2) infection was prevalent in Yuzhou and Zhengzhou. DXP-604 is a broad-spectrum antiviral monoclonal antibody, which has excellent viral neutralization ability in vitro and a long half-life in vivo, with good biosafety and tolerability. Preliminary results showed that DXP-604 can accelerate recovery from Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 Delta variant in hospitalized patients with mild to moderate clinical symptoms. However, the efficacy of DXP-604 has not been fully studied in high-risk severe patients. Here, we prospectively enrolled 27 high-risk patients, two groups were divided, in addition to receiving standard of care (SOC), 14 of them additionally received the neutralizing antibody DXP-604 therapy, and another 13 intensive care unit (ICU) patients simultaneously underwent SOC as a control group matched for age, gender, and clinical type. The results revealed lower C-reactive protein, interleukin-6, lactic dehydrogenase and neutrophil counts, and higher lymphocyte and monocyte counts from Day 3 post-DXP-604 treatment compared with SOC treatment. Besides, thoracic CT images showed improvements in lesion areas and degrees, along with changes in blood inflammatory factors. Moreover, DXP-604 reduced the invasive mechanical ventilation and mortality of high-risk SARS-CoV-2 infected patients. The ongoing clinical trials of DXP-604 neutralizing antibody will clarify its utility as a new attractive countermeasure for high-risk COVID-19.
Keywords: COVID-19; DXP-604; intensive care unit patients; neutralizing antibody.